TIL Instil Bio
- 11.3000
- +0.0800+0.71%
- 11.3300
- +0.0300+0.27%
Instil Bio News
Instil Bio Announces Board Reshuffle Following Resignation
Instil Bio Cut to Hold From Buy by Jefferies
Instil Bio Cut to Hold From Buy by Jefferies
Express News | Jefferies Downgrades Instil Bio to Hold, Raises Price Target to $11
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Instil Bio (TIL) and Regeneron (REGN)
Express News | Instil Bio Inc : Jefferies Raises Target Price to $11 From $5
Express News | Instil Bio Inc : Jefferies Cuts to Hold From Buy
Express News | HC Wainwright & Co. Reiterates Buy on Instil Bio, Maintains $18 Price Target
Instil Bio Non-GAAP EPS of -$1.26 Beats by $2.14
Express News | Instil Bio Q4 Adj EPS $(1.26) Beats $(2.85) Estimate
Instil Bio Sees Cash Runway Beyond 2026 >TIL
Instil Bio Sees Cash Runway Beyond 2026 >TIL
Instil Bio 4Q Loss/Shr $1.99 >TIL
Instil Bio 4Q Loss/Shr $1.99 >TIL
Press Release: Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update DALLAS, March 21, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (Nasdaq: TIL), a clinical-s
Instil Bio Executives Secure Retention Bonus Agreements
Analysts' Top Healthcare Picks: Instil Bio (TIL), Evolus (EOLS)
Instil Bio Is Maintained at Buy by HC Wainwright & Co.
Instil Bio Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on Instil Bio, Adjusts Price Target To $18
Express News | Baird Reiterates Outperform on Instil Bio, Maintains $54 Price Target
Instil Bio Partners for ITIL-306 Preclinical Manufacturing Studies
Instil Bio Hits Four-month High on Rising Volumes
Instil Bio Is Maintained at Outperform by Baird
Instil Bio Is Maintained at Outperform by Baird
Analysis
Price Target
No Data
